HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $10.37 million. The enterprise value is $14.72 million.
Important Dates
The last earnings date was Monday, August 18, 2025, before market open.
| Earnings Date | Aug 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 1.81 million shares outstanding. The number of shares has increased by 33.36% in one year.
| Current Share Class | 1.81M |
| Shares Outstanding | 1.81M |
| Shares Change (YoY) | +33.36% |
| Shares Change (QoQ) | +59.38% |
| Owned by Insiders (%) | 37.96% |
| Owned by Institutions (%) | 4.35% |
| Float | 957,122 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.41 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.87 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.41% |
| Return on Invested Capital (ROIC) | -162.01% |
| Return on Capital Employed (ROCE) | -657.05% |
| Revenue Per Employee | $23,134 |
| Profits Per Employee | -$598,721 |
| Employee Count | 36 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.82% in the last 52 weeks. The beta is 0.67, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -70.82% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 11.02 |
| Relative Strength Index (RSI) | 64.83 |
| Average Volume (20 Days) | 4,524,420 |
Short Selling Information
The latest short interest is 38,223, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 38,223 |
| Short Previous Month | 77,824 |
| Short % of Shares Out | 2.11% |
| Short % of Float | 3.99% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $832,841 and -$21.55 million in losses. Loss per share was -$17.59.
| Revenue | 832,841 |
| Gross Profit | 166,568 |
| Operating Income | -13.56M |
| Pretax Income | -27.39M |
| Net Income | -21.55M |
| EBITDA | -12.04M |
| EBIT | -13.56M |
| Loss Per Share | -$17.59 |
Full Income StatementBalance Sheet
The company has $2.44 million in cash and $6.79 million in debt, giving a net cash position of -$4.35 million or -$2.40 per share.
| Cash & Cash Equivalents | 2.44M |
| Total Debt | 6.79M |
| Net Cash | -4.35M |
| Net Cash Per Share | -$2.40 |
| Equity (Book Value) | -51,972 |
| Book Value Per Share | -0.02 |
| Working Capital | -23.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.56 million and capital expenditures -$150,475, giving a free cash flow of -$12.71 million.
| Operating Cash Flow | -12.56M |
| Capital Expenditures | -150,475 |
| Free Cash Flow | -12.71M |
| FCF Per Share | -$7.01 |
Full Cash Flow StatementMargins
| Gross Margin | 20.00% |
| Operating Margin | -1,627.99% |
| Pretax Margin | -1,368.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.36% |
| Shareholder Yield | -33.36% |
| Earnings Yield | -207.80% |
| FCF Yield | -122.52% |
Analyst Forecast
The average price target for HCW Biologics is $35.00, which is 511.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 511.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 171.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
HCW Biologics has an Altman Z-Score of -7.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.23 |
| Piotroski F-Score | 3 |
